Who are IPV at 14 and fIPV at 22 weeks, RotaTeq's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comirnaty, Prevnar 20, BNT162b5 Bivalent (Original/OMI BA.4/BA.5), FluMist Quadrivalent (2017-2018), MenC, Pandemic influenza A/H1N1 vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ipv-at-14-and-fipv-at-22-weeks-rotateq.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

IPV at 14 and fIPV at 22 weeks, RotaTeq — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IPV at 14 and fIPV at 22 weeks, RotaTeq (IPV at 14 and fIPV at 22 weeks, RotaTeq) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

IPV at 14 and fIPV at 22 weeks, RotaTeq (IPV at 14 and fIPV at 22 weeks, RotaTeq) — Centers for Disease Control and Prevention. IPV (inactivated poliovirus vaccine) and RotaTeq (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IPV at 14 and fIPV at 22 weeks, RotaTeq TARGET	IPV at 14 and fIPV at 22 weeks, RotaTeq	Centers for Disease Control and Prevention	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
BNT162b5 Bivalent (Original/OMI BA.4/BA.5)	bnt162b5-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	mRNA vaccine	Spike protein of SARS-CoV-2
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus
MenC	MenC	Novartis Vaccines	marketed	Conjugate vaccine	Capsular polysaccharide of Neisseria meningitidis serogroup C
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IPV at 14 and fIPV at 22 weeks, RotaTeq — Competitive Intelligence Brief. https://druglandscape.com/ci/ipv-at-14-and-fipv-at-22-weeks-rotateq. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab